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Fibroblasts play an important role as members of the innate immune system through the
secretion of COX-2-derived inflammatory mediators such as prostaglandin E2 (PGE2).
However, it has been described that dermal fibroblasts behave like mesenchymal stem
cells reducing lymphocyte recruitment and dendritic cell activation through PGE2 release.
As the role of fibroblasts in psoriasis remains poorly characterized, in the present study
we have evaluated the possible influence of PGE2 derived from dermal fibroblasts as
modulator of the immune response in psoriatic skin. Our results indicate that under
inflammatory conditions, psoriatic fibroblasts showed defective induction of COX-2,
which resulted in diminished production of PGE2, in contrast to healthy fibroblasts.
This phenotype correlated with deficient c-Jun N-terminal kinase (JNK) activation, in
accordance with the hypothesis that alterations in members of the JNK pathway are
associated with psoriasis. Furthermore, conditioned medium from psoriatic fibroblasts
promoted the polarization of monocytic cells toward a pro-inflammatory profile, effect
that was mimicked in healthy fibroblasts after pre-incubation with indomethacin. These
results are consistent with a prominent role of dermal fibroblasts in the regulation
of inflammatory response through the participation of COX-derived metabolites. This
resolutive behavior seems to be defective in psoriatic fibroblasts, offering a possible
explanation for the chronification of the disease and for the exacerbation triggered by
nonsteroidal anti-inflammatory drugs (NSAIDS) such as indomethacin.
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INTRODUCTION
Psoriasis is a chronic skin inflammatory disease characterized by the appearance of scaly plaques
as result of the interplay of genetic, environmental, and immunological factors (1, 2). From a
pathophysiological perspective, psoriasis is largely caused by an imbalance between the local
immune response and its regulatory mechanisms, mainly involving lymphocytes, dendritic cells,
and keratinocytes (3). Although the participation of other resident cells such as Langerhans cells or
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macrophages has also been recognized (3, 4); the role of
fibroblasts, the main cell type in the dermis, remains relatively
poorly characterized.
Fibroblasts are stromal cells, responsible for the synthesis and
remodeling of extracellular matrix components, which regulate
homeostasis and play a critical role during tissue development,
differentiation, and repair (5). They are also considered members
of the innate immune system and could contribute to the
pathogenesis of several diseases, such as rheumatoid arthritis
or tumor development, through the secretion of cytokines,
chemokines, or eicosanoids (6–8). Interestingly, depending
on their location, fibroblasts are able to display either pro-
inflammatory or anti-inflammatory properties and influence
leukocyte recruitment. Thus, synovial fibroblasts develop a direct
inflammatory phenotype in the inflamed synovium, whereas
dermal fibroblasts are more functionally similar to mesenchymal
stem cells, limiting cytokine sensitivity of vascular endothelium,
lymphocyte recruitment and dendritic cell activation (5, 9, 10).
These regulatory effects are in part mediated by classically
considered pro-inflammatory mediators such as prostaglandin
E2 (PGE2), which is highly produced by healthy dermal
fibroblasts (11, 12).
PGE2, generated by the action of cyclooxygenases
(constitutively active COX-1 and inducible COX-2) on
the membrane phospholipid arachidonic acid, is generally
recognized as a mediator of active inflammation at early stages.
In healthy human fibroblasts, COX-2 is upregulated upon
inflammatory stimulation (13), and released PGE2 supports
the migration of dendritic cells and promotes IL-23 secretion
(14, 15). Paradoxically, PGE2 can suppress both innate and
antigen-specific stimulated immunity in chronic processes by
promoting the induction of suppressive IL-10 and reducing
the production of pro-inflammatory cytokines such as tumor
necrosis factor α (TNF-α) in macrophages (16). Therefore, the
role of PGE2 in psoriasis remains still controversial. Moreover,
administration of non-steroidal anti-inflammatory drugs
(NSAIDs) can exacerbate the symptoms of the disease (17, 18).
There is evidence that fibroblasts isolated from diseased
tissues exhibit phenotypic differences compared with fibroblasts
taken from normal tissues (19). Accordingly, we recently
described that dermal fibroblasts obtained from psoriatic
plaques display a defective activation of the c-Jun N-terminal
kinase (JNK) pathway that leads to diminished cytokine
production (20). In the present study, we sought to further
investigate the role of fibroblasts as modulators of the immune
response in the skin and put in the spotlight the possible
participation of altered psoriatic dermal fibroblasts in the
chronification and exacerbation of this disorder. To do so,




Interleukin-1β (IL-1β) was obtained from Peprotech (Rocky
Hill, NJ). Polyclonal rabbit antibody against COX-2 was
from Millipore (Temecula, CA). Polyclonal goat anti-rabbit
Immunoglobulins/HRP were from Dako (Glostrup, Denmark).
Diaminobenzidine (DAB) was from Vector (Burlingame,
CA). Monoclonal antibodies against phospo-NFκB p65
(Ser536), phospho-p38 (Thr180/Tyr182), phospho-ERK1/2
(Thr202/Tyr204), phospho-SAPK/JNK (Thr183/Tyr185),
and RelB were from Cell Signaling Technology (Beverly,
MA). 12-O-tetradecanoyl phorbol 13-acetate (TPA), 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
and other reagents were from Sigma-Aldrich (St. Louis, MO).
Isolation and Culture of Primary
Human Fibroblasts
All protocols and procedures were approved by the University
of Valencia Ethical Committee (number of procedure:
H1396456196160) and carried out according to the Declaration
of Helsinki Principles. Tissue samples were obtained from
programmed clinical interventions and donors signed the
informed consent to use the samples for research purposes.
Primary fibroblasts were obtained from freshly resected
foreskins of 14 adult healthy donors (25.8± 2.3 years, Caucasian)
and from lesional skin biopsies taken for diagnosis purposes
of 14 psoriatic patients (42.9 ± 15.7 years, Caucasian, 10 men
and 4 women, PASI = 10.2 ± 15.9) (Table S1). Patients had
received no topical treatment for at least 2 weeks and no systemic
treatment for at least 4 weeks before the procedure and diagnosis
of plaque-type psoriasis was confirmed by histological analysis.
Skin samples were cut into small pieces and incubated overnight
at 4◦C in 0.5% dispase II. Epidermis was removed and dermis
was digested during 90min at 37◦C in 0.1% collagenase IA.
Suspension was passed through a 70µm filter and centrifuged.
Cells obtained directly after digestion were cultured at 37◦C, 5%
CO2 in DMEM/F12 HAMmedium supplemented with 10% FBS
(Biowest, Nuaillé, France) and 1% penicillin/streptomycin. After
reaching 80–90% confluence, cells were passaged using 0.25%
trypsin. Cultured cells from freshly isolates were used between
passages 2 and 5.
MTT Assay and Radioimmunoassay
Cells were seeded in 24-well culture plate (50,000 cells/well).
Next day, medium was replaced and cells were stimulated with
2.5 ng/ml IL-1β or 1µg/ml TPA. After 24 h, supernatants
were collected and remaining fibroblasts were used to
determine the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) to formazan. PGE2 release
was determined in the supernatants by radioimmunoassay
(RIA) (21).
Western Blotting
To assess the induction of COX-2, cells were seeded in 6 cm
Petri dishes (500,000 cells/dish). Next day, medium was replaced
and cells were stimulated with 2.5 ng/mL IL-1β or 1µg/mL
TPA during 24 h. IL-1β treated supernatants were collected
(conditioned medium) and cells whole protein extraction was
carried out with RIPA buffer (50mM Tris, 150mM NaCl,
0.5% Sodium Deoxycholate, 1% Triton X-100) containing an
antiprotease cocktail (21). RelB expression was measured at 6 h
post stimulation.
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To study the phosphorylation of MAPKs and NF-κB, cells
were seeded in 6 cm Petri dishes (500,000 cells/dish) until
confluence and subsequently starved during 6 h with medium
without FBS. After 15-min stimulation with 2.5 ng/ml IL-1β or
1µg/ml TPA, whole cell protein extraction was carried out with
RIPA buffer containing an antiprotease cocktail.
Western blot of all lysates was performed as previously
described (22). Images were captured with the AutoChemi image
analyzer (UVP Inc., Upland, CA). GAPDH was used as a protein
loading control.
Immunocytochemistry
Cells were seeded in 8-wells chambers (50,000 cells/well). Next
day, medium was replaced and cells were stimulated during 24 h
as above. After 15min fixation with paraformaldehyde 4% and
peroxidase blocking (Dako, Copenhagen, Denmark), cells were
incubated 2 h with COX-2 antibody and 1 h with secondary HRP
anti-rabbit antibody. Development of the peroxidase staining
was performed with DAB and visualized in Leica DM IL LED
microscope, using Leica Application Suite (Solms, Germany).
RNA Extraction and Real-Time
Quantitative RT-PCR
Cells were seeded in 6 cm Petri dishes (500,000 cells/dish).
When confluence was reached, medium was renewed and
cells were stimulated with 2.5 ng/ml IL-1β or 1µg/ml TPA.
Total RNA was extracted using TriPure Isolation Reagent
(Roche, Mannheim, Germany). cDNA of COX-2 and GAPDH
were obtained using ImProm-II Reverse Transcription System
(Promega Corporation, Madison, WI). cDNA of miR-146a
and U6 were obtained using TaqMan MicroRNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA).
All cDNAs were quantified via real-time PCR using
Taqman 20x Assays-On-Demand (FAM-labeled MGB-
probes) gene expression assay mix (Applied Biosystems;
assay ID: Hs00153133_m1, Hs00377726_m1, HS99999905_m1,
4427975-000468, and 4395470-001973, respectively) and
Taqman Universal PCR Master Mix No AmpErase UNG
(Applied Biosystems).
The expression levels were analyzed on a StepOnePlus
machine (Applied Biosystems) and normalized to the
housekeeping GAPDH or U6.
Macrophages-Derived THP-1 Culture
THP-1 cells were cultured at 37◦C, 5% CO2 in RPMI medium
supplemented with 10% SBF and 1% penicillin/streptomycin.
Differentiation of THP-1 to macrophages was performed seeding
THP-1 in 24-well plates (400,000 cells/well) and incubating them
with TPA 10 nM during 3 days. Then, adherent cells were washed
with DMEM and incubated for 24 h with conditioned media
from psoriatic fibroblast (PFCM) or healthy fibroblasts (HFCM)
previously stimulated with IL-1β (2.5 ng/ml) during 24 h. In other
set of experiments, THP-1 cells were incubated during 24 h with
PGE2 (30 ng/ml), indomethacin (10µM), or their combination
in the presence or absence of IL-1β (2.5 ng/ml) in DMEM/F12
HAMmedium.
Statistical Analyses
Results are presented as mean ± SD. Statistical analyses were
performed using either two-way ANOVA followed by Sidak’s
multiple comparison test or one-way ANOVA followed by
Tukey’s multiple comparison test, carried out by GraphPad Prism
4 software (GraphPad Software, Inc., San Diego, CA). A value of
p < 0.05 was considered statistically significant.
RESULTS
Failure to Induce COX-2 Expression
Resulted in Reduced Production of PGE2
by Dermal Fibroblasts From
Psoriatic Plaques
Several studies using fibroblasts obtained from surgical resections
of healthy skin suggest that PGE2 may contribute to psoriasis
pathogenesis by promoting recruitment and activation of T-
cells, dendritic cells and monocytes (14, 15). Nonetheless, PGE2
also has anti-inflammatory effects that are both potent and
context dependent (23). To explore the production of this
prostaglandin by plaque-type psoriatic fibroblasts, we selected
two different stimuli: IL-1β (2.5 ng/ml), which potently induces
COX-2 expression in healthy fibroblasts (24); and the direct
protein kinase C (PKC) activator, 12-O-tetradecanoylphorbol-
13-acetate (TPA, 1µg/ml), which triggers epidermal hyperplasia
in vivo (22) and induces COX-2 expression by a receptor-
independent mechanism (25). After discarding the possible
cytotoxicity by the MTT assay (Figure 1A), release of PGE2 was
determined in cell supernatants by radioimmunoassay. Results
showed that psoriatic fibroblasts failed to produce a significant
increase of PGE2 after 24 h stimulation with either stimulus,
in contrast to fibroblasts from surgical resections of healthy
donors (Figure 1B). It is interesting to note that basal levels of
this eicosanoid were also significantly lower in psoriatic than in
healthy fibroblasts.
Western blot analysis, performed using the above
experimental conditions, confirmed that the lower production
of PGE2 by psoriatic fibroblasts correlated with a failure
to induce COX-2 expression. As seen in Figure 1C, IL1-β
markedly induced COX-2 expression in healthy fibroblasts,
whereas a non-significant increase was observed in psoriatic
fibroblasts (Figures 1C,D). Similar effects were obtained
by immunocytochemistry, which only revealed a slight
positive response in IL1-β-treated psoriatic fibroblasts
compared to the pronounced expression obtained in healthy
fibroblast (Figure 1E).
To assess the possible deficiency at mRNA expression level,
psoriatic and healthy fibroblasts were treated with TPA or IL1-
β for 3, 6, 9, and 24 h and COX-2 mRNA was determined
by real-time reverse transcriptase PCR (RT-PCR). The slight
increase of COX-2 mRNA expression in psoriatic fibroblasts
induced by either stimulus at several times was not statistically
significant, in contrast to mRNA increase obtained using
healthy fibroblasts (Figures 2A,B). Since basal PGE2 levels by
unstimulated psoriatic fibroblasts were reduced, we determined
mRNA expression of the constitutive COX-1. Our results show
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FIGURE 1 | PGE2 production and COX-2 expression are decreased in stimulated psoriatic fibroblasts. Cells were treated with 2.5 ng/ml IL-1β or 1µg/ml TPA for 24 h.
(A) 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for cell viability (n = 4 biopsies) and (B) Prostaglandin E2 (PGE2 ) determined by
radioimmunoassay (n = 6 biopsies) were performed in duplicate. (C,D) COX-2 protein expression assessed by Western blotting (n = 3 biopsies). Data represent mean
± SD. *p < 0.05, ***p < 0.001 vs. unstimulated fibroblasts (B) and +p < 0.05, +++p < 0.001 vs. healthy fibroblasts (HF) using Sidak’s multiple comparison test. PF,
psoriatic fibroblasts. (E) COX-2 protein expression determined by immunocytochemistry (representative photomicrographs of three independent experiments).
that TPA was able to induce a significant increase of mRNA
levels in healthy fibroblasts, whereas mRNA expression remained
similar before and after IL1-β stimulation. Psoriatic fibroblasts
followed a similar pattern of expression, but COX-1mRNA levels
were always lower than in healthy fibroblasts (Figure 2C).
Defective Activation of the JNK Pathway in
Psoriatic Fibroblast Would Lead to
Reduced COX-2 Expression
A similar deficit in COX-2 induction and subsequent PGE2
production has been described in fibroblasts from other
pathological conditions such as asthma (26, 27) and idiopathic
pulmonary fibrosis (28, 29). It has been described that COX-2
transcription in nasal fibroblasts is critically governed bymitogen
activated protein kinases (MAPKs) and the NF-κB complex
(26). However, the non-canonical NF-κB member RelB exerts
anti-inflammatory effects in IL-1β-stimulated lung fibroblasts by
upregulating miR-146a, which would efficiently degrade COX-2
mRNA (30). Therefore, we sought to determine the canonical
and non-canonical NF-κB pathways in psoriatic fibroblasts.
Immunoblotting of the phosphorylation of NF-κB p65 after
15min stimulation with IL-1β or TPA showed the same grade of
activation in both, healthy and psoriatic fibroblasts (Figure 3A).
We observed as well that RelB was similarly expressed in
healthy and psoriatic fibroblasts at basal conditions or after
6 h stimulation (Figure 3B). In addition, miR-146a expression
determined by RT-qPCR was induced in a time-dependent
manner by IL1-β and TPA, but no differences were found
between psoriatic and healthy fibroblasts (Figures 3C,D).
With respect to the possible alteration of MAPKs
activation pathways, there were no differences between
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FIGURE 2 | COX-1 and COX-2 mRNA expression is decreased in psoriatic
fibroblasts. Cells were treated with 2.5 ng/ml IL-1β (A) or 1µg/ml TPA (B) for
3, 6, 9, or 24 h and COX-2 mRNA levels were evaluated by quantitative
real-time PCR. (C) COX-1 mRNA levels were evaluated by quantitative PCR
after IL-1β or TPA stimulation during 6 h. Data represent mean ± SD (n = 6
biopsies) of mRNA expression normalized to the housekeeping gene GAPDH
and expressed as 2−11CT values. ***p < 0.001 vs. unstimulated healthy
fibroblasts (B) and +p < 0.05, ++p < 0.01, +++p < 0.001 vs. healthy
fibroblasts (HF) using Sidak’s multiple comparison test. PF, psoriatic fibroblasts.
psoriatic and healthy fibroblasts in the phosphorylation of
MAPKs p38 and extracellular signal-regulate kinase (ERK)
1/2. However, both stimuli, IL-1β and TPA, caused less
activation of SAPK/JNK in psoriatic fibroblasts than in healthy
fibroblasts (Figures 3E,F).
To prove the regulatory role of SAPK/JNK in COX-
2 expression by dermal fibroblasts, we preincubated healthy
fibroblasts with the JNK inhibitor SP600125 (50µM) prior to
2 h stimulation with IL-1β or TPA. RT-qPCR analysis showed
that SP600125 significantly diminished COX-2mRNA levels after
both stimuli (Figure 3G). These results confirm that SAPK/JNK
is directly involved in the COX-2 expression in dermal fibroblasts
and suggest that its downregulation could be responsible, at
least in part, of the failure in COX-2 induction observed in
psoriatic fibroblasts.
Defective Induction of COX-2 Expression
by Psoriatic Fibroblasts Promotes the
Polarization of Macrophages to a
Pro-inflammatory Phenotype
The interplay between fibroblasts and macrophages is crucial to
maintain and to re-establish the integrity of the dermis. Both
cell types are key players during the local inflammatory response
triggered by tissue injury and also in the subsequent resolution
phase (31, 32). Macrophages display different phenotypes
depending on the inflammatory environment, leading to the
resolution or the aggravation of the inflammatory process
(33). In psoriatic lesions, classically activated macrophages
represent an important source of TNF-α, a cytokine highly
involved in the pathogenesis of the disease (4, 34, 35).
Furthermore, a reduction of IL-10 levels has been described
in psoriatic lesions (36). Thus, we decided to determine the
possible influence of fibroblasts on the macrophage response.
For this purpose, conditioned media collected from healthy
and psoriatic fibroblasts stimulated during 24 h with IL-1β
were added to THP-1-derived macrophage cultures, and the
release of TNF-α and IL-10 was determined. Macrophages
incubated during 24 h with stimulated psoriatic fibroblast
conditioned media (PFCM) exhibited a clear pro-inflammatory
profile, producing high levels of TNF-α and low levels of
the anti-inflammatory cytokine IL-10 (Figure 4A). In contrast,
macrophages incubated with stimulated healthy fibroblast
conditioned media (HFCM), produced low levels of TNF-
α and high amount of IL-10, suggesting a physiological
regulatory profile.
In order to emulate the decreased expression of COX-2 found
in psoriatic fibroblasts, the non-selective COX-1 and COX-
2 inhibitor, indomethacin (10µM), was used to treat healthy
fibroblasts prior to IL-1β-stimulation, and macrophages were
incubated with conditioned medium. Under these conditions,
macrophages produced high levels of TNF-α and low levels of
IL-10 in a similar manner to macrophages incubated with PFCM
(Figure 4A). These results suggested a possible regulatory role of
PGE2 produced by healthy fibroblasts on macrophage activation,
which could be lost in psoriatic fibroblasts due to the decrease in
their ability to produce this eicosanoid.
To further demonstrate the effect of PGE2, macrophages
were directly stimulated with IL-1β in the presence or
absence of 30 ng/ml exogenous PGE2 (concentration detected in
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FIGURE 3 | Psoriatic fibroblasts show an altered activation of the SAPK/JNK pathway involved in COX-2 induction. (A) Representative immunoblotting image of
phosphorylated NF-κB p65 subunit after 15min treatment with 2.5 ng/ml IL-1β or 1µg/ml TPA. (B) Representative immunoblotting image of phosphorylated NF-κB
RelB subunit after 6 h treatment with IL-1β or TPA. (C,D) miR146a expression determined by RT-qPCR at 0, 3, 6, or 9 h post stimulation with IL-1β or TPA. Data
represent mean ± SD (n = 4 biopsies) of 2−11CT values normalized to the small nucleolar RNA U6. *p < 0.05, ***p < 0.001 vs. non stimulated (B) healthy fibroblasts
(HF) and ###p < 0.001 vs. non stimulated (B) psoriatic fibroblasts (PF) using Sidak’s multiple comparison test. (E) Representative immunoblotting image of
phosphorylated p38, ERK1/2, and SAPK/JNK after 15min stimulation with IL-1β or TPA. (F) Densitometry analysis of phospho SAPK/JNK immunoblots. Data
represent mean ± SD (n = 4). ***p < 0.001 vs. non stimulated (B) healthy fibroblasts (HF); #p < 0.05, ##p < 0.01 vs. non stimulated (B) psoriatic fibroblasts (PF) and
+++ p < 0.001 vs. healthy fibroblasts (HF) using Sidak’s multiple comparison test. (G) RT-qPCR for COX-2 mRNA in HF after preincubation with the JNK inhibitor
SP600125 (50µM) during 45min and the subsequently stimulation with IL-1β (n = 6 biopsies) or TPA (n = 8 biopsies) during 2 h. Data represent mean ± SD. **p <
0.01, ***p < 0.001 vs. unstimulated cells (B); +p < 0.05, ++p < 0.01 vs. IL-1β/TPA stimulated fibroblasts using Tukey’s multiple comparison test.
supernatants of healthy fibroblasts after 24 h stimulation with IL-
1β, Figure 1B). As shown in Figure 4B, exogenous PGE2 induced
a regulatory phenotype in stimulated macrophages, reducing
the production of TNF-α and prompting the production of
IL-10, regardless the presence of indomethacin. Interestingly,
pre-treatment with indomethacin supported an inflammatory
behavior in stimulated macrophages, maintaining high levels of
TNF-α, but blunting the production of IL-10.
DISCUSSION
Recent studies suggest that tissue-resident stromal cells such
as fibroblasts are critically positioned at the cellular and
molecular basis for disease persistence, as regulators of the
switch from acute resolving to chronic persistent inflammation
(5). Fibroblasts from healthy tissues predominantly exhibit
a regulatory and immunomodulatory phenotype, whereas
fibroblasts from diseased tissues display pro-inflammatory
characteristics and promote leucocyte recruitment (10, 12). In
the synovial joint, fibroblast-like synoviocytes amplify tissue
damage through the production of eicosanoids, cytokines and
proteases (37). In certain types of cancers, including colon,
breast and prostate, a specific population of cancer-associated
fibroblasts (CAFs) strongly induce COX-2 and secrete PGE2,
which results essential in tumor survival and metastasis (7, 8,
38–40). In psoriatic dermis, a positive COX-2 immunostaining
was previously described, although the main cell type involved
(inflammatory or stromal cells) remains unclear (15, 41). Thus,
we decided to investigate the role of PGE2 derived from dermal
fibroblast in the pathogenesis of psoriasis. Unexpectedly, our
results demonstrated a disability of psoriatic fibroblasts to induce
COX-2 and generate PGE2 under inflammatory conditions. Even
constitutive COX-1 was less expressed in psoriatic than in healthy
fibroblasts, in accordance with Niu et al. (42), who described a
significant decrease in COX-1 expression by mesenchymal stem
cells derived from dermis of psoriatic lesions compared to healthy
Frontiers in Immunology | www.frontiersin.org 6 March 2019 | Volume 10 | Article 536
Arasa et al. Defective COX-2 in Psoriatic Fibroblasts
FIGURE 4 | Psoriatic fibroblasts support pro-inflammatory activation of macrophages. (A) TNF-α and IL-10 levels in THP-1 derived macrophages incubated during
24 h with conditioned media from IL-1β-stimulated psoriatic fibroblast (PFCM) (n = 4 biopsies) or IL-1β-stimulated healthy fibroblasts (HFCM) (n = 4 biopsies). When
indicated, healthy fibroblasts where pretreated with 10µM indomethacin (Indo) before stimulation. Data represent mean ± SD. **p < 0.01, ****p < 0.0001 respect
untreated macrophages (B); +++p < 0.001 ++++p < 0.0001 vs. macrophages treated with HFCM using Tukey’s multiple comparison test. (B) TNF-α and IL-10
levels in THP-1 derived macrophages treated during 24 h with PGE2 (30 ng/ml), indomethacin (10µM) or their combination in the presence or the absence of IL-1β
(2.5 ng/ml). Data represent mean ± SD (n = 6). ***p < 0.001, ****p < 0.0001 vs. untreated cells (B). +++p < 0.001 respect IL-1β-treated cells using Tukey’s multiple
comparison test. All conditions were assayed in duplicate.
controls. Interestingly, a similar behavior has been described in
other diseases such as idiopathic pulmonary fibrosis and chronic
asthma, where the inability of lung fibroblasts to upregulate PGE2
in response to a cytokine stimulus seems to contribute to the
evolution of airway fibrosis (27, 28, 43).
In view of our results, PGE2 derived from healthy fibroblasts
would exert a regulatory function, as previously described
(16, 23), which is lost in psoriatic fibroblasts, contributing to
the lack of control of cellular infiltration and inflammatory
response. This hypothesis gets reinforced by the fact that
COX-derived mediators released by dermal fibroblasts promote
alternative macrophage activation improving wound healing
(32). In particular, PGE2 has a profound effect on macrophages
(44), favoring the conversion of pro-inflammatory macrophages
to a more anti-inflammatory phenotype (45). Nevertheless,
dermal fibroblasts produce other prostanoids besides PGE2, such
as PGE1, PGD2, PGF2α, or PGJ2 (46, 47), and it has been
shown that both PGE2 and PGD2 from conditioned medium of
stimulated myofibroblasts promote an alternative macrophage
activation, which is abrogated by indomethacin and selective
COX-2 inhibitors, suggesting a principal role of this isoenzyme
in wound healing (48).
Our results suggest that COX-derived products of dermal
fibroblasts favor the alternative differentiation of macrophages
toward a resolutive phenotype, which is defective in psoriatic
skin. In support of this hypothesis, a clinical exacerbation of
psoriasis after administration of NSAIDs, such as indomethacin
and phenylbutazone, has been described; although the use of
NSAIDs is rarely discouraged by dermatologists in patients with
psoriasis (17).Moreover, in a small clinical trial involving patients
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with plaque-type psoriasis, topical application of a PGE2 gel
(5 mg/g, under occlusive dressing) improved certain signs of
psoriatic lesions in comparison to gel alone, without completely
clearing them (49). The search for the molecular mechanism
responsible for the decrease of COX-2 and PGE2 in psoriatic
fibroblasts led us to detect a failure in the phosphorylation of
the SAPK/JNK pathway. In this sense, mutations in different
members of the JNK pathway have been associated with psoriasis.
Thus, JunB gene is located in the psoriasis susceptibility region
PSORS6, and epidermal deletions of JunB and c-Jun in mice lead
to psoriasis-like lesions (50). Additionally, it has been described
that knock out fibroblasts in JNK compromise the normal
differentiation and proliferation of keratinocytes, suggesting a
pivotal role of fibroblast-derived soluble factors in the efficiency
of wound healing (51). In this context, we recently described
that defective production of IL-6 in psoriatic fibroblasts was also
related to the downregulation of SAPK/JNK pathway (20). In our
studies, we observed similar low levels of phosphorylatedMAPKs
in unstimulated serum-deprived normal and psoriatic fibroblasts,
as previously described by Dimon-Gadal et al. (52). In contrast,
Becatti et al. (53) reported an altered phosphorylation of JNK
as well as p38 and ERK in basal psoriatic fibroblasts respect to
healthy cells, possibly due to different experimental conditions.
Interestingly, they reported that psoriatic fibroblasts showed
reduced expression and activity of Sirtuin 1 (SIRT1), which
was responsible for the loss of protective mechanisms against
oxidative stress and redox balance (53). In a similar manner,
Guban et al. (54) have also recently suggested that defective
activation of STAT1 in fibroblasts from psoriatic patients could
be related to the physiopathology of the disease.
Taken together, our study is consistent with a role for
fibroblasts in the regulation of skin inflammation (10) and the
hypothesis that chronic inflammation may persist as a result of
failure of the processes involved in tissue repair (19). Considering
that fibroblasts maintain their topographic differentiation in
culture (5), our results suggest that psoriatic fibroblasts could
undermine the ability to correctly solve any tissue damage
occurred in periods of remission. Therefore, fibroblasts represent
a very interesting target in the treatment of chronic inflammatory
diseases, such as psoriasis. For this, it is essential to deepen in
the characterization of psoriatic fibroblasts from lesional and
uninvolved skin, looking for potential epigenetic mechanisms
responsible for changes in stromal cell phenotype and their
significance in disease initiation and progression.
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